Shots: Yuhan to receive $40M as upfront & near-term payment and up to $830M milestones and royalties on sales. BI focuses to develop NASH treatment targeting key drivers of the disease i.e, steatosis, inflammation and fibrosis The focus of the collaboration is to develop dual agonist combining GLP-1 and FGF21 activity in a single molecule […]Read More
Shots: Insitro to receive $15M upfront, $35M near term operational milestone, $200M as preclinical, development, regulatory and commercial milestones on each 5 targets & royalties on sales. Insitro has also an option to co-develop & co-detail in the US with profit share in China and will receive milestones and royalties on sales (Ex-US) Gilead will […]Read More
Shots: The P-III STELLAR-4 study involves assessing of Selonsertib (18mg, 6mg, qd) vs PBO (qd) in patients with compensated cirrhosis (F4) due to NASH for 240 wks. The P-III study didn’t meet its 1EPs @48wks., achieved a ≥ 1-stage improvement in fibrosis (14.4%, 12.5% or 12.8%) and was well-tolerated with safe results Selonsertib is qd […]Read More
Copyright ©2021 PharmaShots | Powered by Octavus Consulting
